HealthStream Earnings Call Transcripts
Fiscal Year 2025
-
Full-year 2025 saw 4.3% revenue and 7.5% Adjusted EBITDA growth, with strong Q4 results and robust performance from core products. Two acquisitions and increased capital returns supported expansion, while 2026 guidance projects continued growth and margin improvement.
-
Record Q3 revenue and profit growth driven by strong SaaS subscription performance, with core products like CredentialStream and ShiftWizard posting double-digit gains. Guidance for 2025 remains steady, factoring in new acquisitions and legacy product declines.
-
Record Q2 revenue and strong income growth were driven by robust subscription product performance and major enterprise deals. AI innovation and the HLX launch mark strategic advances, while gross margin remains pressured by cloud costs. Guidance for 2025 is reaffirmed.
-
Revenue grew 1% year-over-year, with strong performance in core SaaS products offset by declines in legacy lines and delayed deal closures. Guidance was revised downward due to temporary implementation and sales delays, but management remains confident in long-term growth and strong cash flow.
Fiscal Year 2024
-
Delivered strong 2024 results with revenue up 4.5% and net income up 31.5% year-over-year. SaaS products drove growth, while legacy product declines and customer bankruptcies posed headwinds. 2025 guidance projects continued growth, with major investments in platform innovation and capital allocation.
-
Record Q3 revenue and Adjusted EBITDA were driven by strong growth in core SaaS products and new product launches, offsetting declines in legacy lines. Guidance was slightly lowered due to a large customer’s slower content consumption, but sales pipelines and market expansion remain robust.
-
Q2 saw 3.4% revenue growth and strong sales in key SaaS products, despite headwinds from a major customer bankruptcy and a timing anomaly. Guidance for 2024 was reiterated, with sequential growth expected in the second half and continued investment in platform integration and new markets.